Gila Therapeutics Completes Phase I Clinical Trial

Gila Therapeutics Completes Phase I Clinical Trial

Obesity drug developer, Gila Therapeutics, recently took a big step toward FDA approval for its new weight control treatment, completing its Phase I clinical trial in August. Gila is developing a novel intra-oral delivery of PYY, a well-known satiety hormone, to help... Read more
John Talley Turns His Attention to Cancer Therapy

John Talley Turns His Attention to Cancer Therapy

For Euclises, it’s simple. Without the work of John Talley, Ph.D., the world would not have Celebrex®, the blockbuster arthritis treatment that has generated in excess of $3.5 billion in sales for Pfizer. Or Dynastat®, an injectable COX-2 inhibitor that’s sold in... Read more